SCHEMBL12459199

SCHEMBL12459199

CC1=CCCc2ncccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.47
TBXAS1 P24557 3/20 0.47
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
CCR1 P32246 3/20 0.34
CCR8 P51685 3/20 0.34
CCR5 P51681 2/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
HSP90AA1 P07900 2/20 0.32
TDP2 O95551 1/20 0.32
NSD2 O96028 1/20 0.32
ABL1 P00519 1/20 0.32
PLCG1 P19174 1/20 0.32
CES1 P23141 1/20 0.32
PAX8 Q06710 1/20 0.32
RIN1 Q13671 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25776767 0.89 CYP19A1 (0.38) CYP19A1TBXAS1NOS3NOS1NOS2
SCHEMBL27890627 0.81 CYP19A1 (0.47) CYP19A1TBXAS1NOS3NOS1NOS2
SCHEMBL13409634 0.80 NOS3 (0.39) CYP19A1TBXAS1NOS3NOS1NOS2
SCHEMBL28010992 0.77 CYP19A1 (0.47) CYP19A1TBXAS1CCR1CCR8CCR5
SCHEMBL24097109 0.77 CYP19A1 (0.43) CYP19A1TBXAS1
Hydrochloric Acid SCHEMBL27549267 0.76 CYP19A1 (0.46) CYP19A1TBXAS1CCR1CCR8CCR5
SCHEMBL22579802 0.74 TDP1 (0.42) CYP19A1TBXAS1CCR1CCR8CCR5
SCHEMBL3860294 0.73 CYP19A1 (0.43) CYP19A1TBXAS1CYP3A4HTT
SCHEMBL3892087 0.71 CYP19A1 (0.60) CYP19A1TBXAS1TDP1GAAL3MBTL1
SCHEMBL28125072 0.71 L3MBTL1 (0.40) CYP19A1TBXAS1TDP1TDP2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021249449-A1 SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2021-12-16 WO disclosed
WO-2011097166-A2 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN HDAC INHIBITOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-08-11 WO disclosed
US-20110077265-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077265-A1 INHIBITORS OF IAP XIAP, BIRC5, BIRC2 CYP19A1 4303/4885TBXAS1 2996/4885NOS3 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.